PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMexiletine hcl
Mexiletine hydrochloride
Mexiletine, Namuscla (mexiletine hydrochloride) is a small molecule pharmaceutical. Mexiletine hydrochloride was first approved as Mexitil on 1985-12-30. It is used to treat cardiac arrhythmias, diabetic neuropathies, ventricular fibrillation, and ventricular premature complexes in the USA. It has been approved in Europe to treat myotonic disorders.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
cardiovascular diseasesD002318
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
mexiletine hcl2008-04-29
mexiletine hydrochlorideANDA2025-02-05
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BB: Antiarrhythmics, class ib
— C01BB02: Mexiletine
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544——1———1
Hiv infectionsD015658EFO_0000764B20—1———1
Peripheral nervous system diseasesD010523—G64—1———1
Acquired immunodeficiency syndromeD000163EFO_0000765B20—1———1
Communicable diseasesD003141———1———1
Nervous system diseasesD009422—G00-G99—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMexiletine hydrochloride
INNmexiletine
Description
Mexiletine is an aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol. It has a role as an anti-arrhythmia drug. It is an aromatic ether and a primary amino compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cccc(C)c1OCC(C)N.Cl
Identifiers
PDB—
CAS-ID5370-01-4
RxCUI—
ChEMBL IDCHEMBL1200606
ChEBI ID6917
PubChem CID4178
DrugBankDB00379
UNII ID1U511HHV4Z (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,805 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
816 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use